Zydus Lifesciences Q1 FY27 Results: Revenue Rs 8,017 Cr, PAT Rs 952 Cr and Key Highlights
- August 12, 2026
- Posted by: Lakshit Sharma
- Category: News
Zydus Lifesciences Q1 FY27: Revenue Rs 8,017 Cr (+21.96% YoY). PAT Rs 952 Cr (-35.93% YoY). Results August 11, 2026. CMP Rs 1,191.
Zydus Lifesciences Q1 FY27 results were announced on August 11, 2026, reporting a net profit (PAT) of Rs 952 crore, down 35.93% from Rs 1,486 crore in Q1 FY26. Revenue from operations grew 21.96% year on year to Rs 8,017 crore from Rs 6,573 crore in Q1 FY26. The Zydus Lifesciences Q1 FY27 results are on a consolidated basis for the quarter ended June 30, 2026.
Click Here – Get Free Investment Predictions
Zydus Lifesciences Q1 FY27 Financial Highlights
The table below summarises the key financial metrics from the Zydus Lifesciences Q1 FY27 results compared with the same quarter of the previous year (Q1 FY26).
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue from Operations (Rs Cr) | Rs 8,017 Cr | Rs 6,573 Cr | +21.96% |
| Gross Profit (Rs Cr) | Rs 1,374 Cr | Rs 1,850 Cr | -25.71% |
| Net Profit / (Loss) – PAT (Rs Cr) | Rs 952 Cr | Rs 1,486 Cr | -35.93% |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends and growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks on Univest
Zydus Lifesciences Q1 FY27 Performance Analysis
Use the Univest Screener to Track Live Fundamentals of Indian Stocks
Zydus lifesciences q1 fy27 results show revenue growth of 21.96% year on year to Rs 8,017 crore. Gross profit declined to Rs 1,374 crore from Rs 1,850 crore in Q1 FY26.
Net profit in the June 2026 quarter stood at Rs 952 crore, a 35.93% decrease year on year. Investors tracking Zydus Lifesciences quarterly results should verify these figures against the official BSE and NSE filings.
Key Business Factors in Zydus Lifesciences Q1 FY27
1. Revenue Trend Sets the Quarterly Context
Revenue grew 21.96% year on year to Rs 8,017 crore, signalling steady demand conditions in the Pharmaceuticals business.
2. Gross Profit and Margin Movement
Gross profit fell to Rs 1,374 crore from Rs 1,850 crore in Q1 FY26. Higher input costs or pricing pressure weighed on gross margins.
3. Net Profit Outcome in the June Quarter
PAT came in at Rs 952 crore, down 35.93% from Rs 1,486 crore in Q1 FY26. Consistent profitability will depend on revenue momentum and margin trends through FY27.
Dividend Details
No dividend has been declared alongside the Zydus Lifesciences quarterly results for the quarter ended June 2026. Investors may track future announcements via BSE India and NSE India portals.
Zydus Lifesciences FY27 Outlook After Q1 Results
Zydus Lifesciences Q1 FY27 results set a broadly positive tone for the full financial year. Revenue grew 21.96% yoy to rs 8,017 crore from rs 6,573 crore a year earlier and a net profit (PAT) of Rs 952 crore provide a foundation for further improvement. Investors monitoring Zydus Lifesciences Q1 results should track demand conditions in Pharmaceuticals, input cost trajectories, and any capacity or business expansion announcements that could shape earnings through the remainder of FY27.
Zydus Lifesciences Stock Performance
Download the Univest iOS App or Univest Android App to track Zydus Lifesciences live share price and upcoming quarterly results.
Zydus Lifesciences share price stood at Rs 1,191 on August 11, 2026, the day the quarterly results were declared. Post-results, the market will assess whether the Pharmaceuticals company’s financial performance justifies the current valuation. Investors should verify the latest price and fundamentals on BSE and NSE before making any investment decision.
Key Risks to Watch After Zydus Lifesciences Q1 FY27 Results
1. Sector-Specific Demand Headwinds
A slowdown in the Pharmaceuticals sector could weigh on Zydus Lifesciences revenue and profitability beyond what the June 2026 quarter already reflects.
2. Input Cost and Margin Pressure
Rising raw material or operational costs could compress gross margins and limit net profit recovery in subsequent quarters of FY27.
3. Macroeconomic and Regulatory Uncertainty
Inflation, interest rate movements, and regulatory changes remain key risks to the earnings trajectory of Zydus Lifesciences through FY27.
Conclusion
Zydus Lifesciences Q1 FY27 results report revenue of Rs 8,017 crore and a net profit (PAT) of Rs 952 crore, down 35.93% from Rs 1,486 crore in Q1 FY26. The June 2026 quarterly performance reflects the company’s position in the Pharmaceuticals space. Investors should study the full financials on BSE and NSE and consult a SEBI-registered advisor before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Zydus Lifesciences Q1 FY27 Results
When were the Zydus Lifesciences Q1 FY27 results announced?
Ans. The June 2026 quarterly results for Zydus Lifesciences were announced on August 11, 2026, covering the quarter ended June 30, 2026. The consolidated results were filed with BSE and NSE on the same date.
What is the PAT in the Zydus Lifesciences Q1 FY27 results?
Ans. PAT (net profit) stood at Rs 952 crore in the June 2026 quarter, down 35.93% from Rs 1,486 crore in Q1 FY26.
What was the revenue in the Zydus Lifesciences Q1 FY27 results?
Ans. Revenue for the June 2026 quarter rose 21.96% year on year to Rs 8,017 crore from Rs 6,573 crore in Q1 FY26.
Did Zydus Lifesciences announce any dividend with the Q1 FY27 results?
Ans. No dividend has been declared alongside the June 2026 quarterly results. Investors may track future Zydus Lifesciences dividend announcements through the BSE and NSE portals.
What is the Zydus Lifesciences FY27 outlook after Q1 results?
Ans. The June 2026 quarterly performance signals a positive start to FY27 for Zydus Lifesciences. Key factors to watch include revenue trends, margin performance, and Pharmaceuticals sector demand through the rest of the financial year.
Is Zydus Lifesciences a good buy after Q1 FY27 results?
Ans. The Q1 FY27 financial performance of Zydus Lifesciences reflects challenging trends in the June 2026 quarter. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor.